Posted by Michael Wonder on 12 Mar 2020
U.S. government aims at high insulin prices with plan for $35 copay in Medicare
11 March 2020 - The Trump administration on Wednesday turned back to its pledge to fight high U.S. drug prices with a plan to limit the out-of-pocket cost for insulin, a life-saving medicine, to $35 per month for many people with diabetes who are enrolled in Medicare.
The Center for Medicare and Medicaid Services, part of the U.S. Department of Health and Human Services, is lining up drug makers and the private insurers who manage Medicare drug benefits to volunteer to test out the new pricing in 2021.
Medicare drug plans cover about 46 million people aged 65 and older and with disabilities.
